Predicted protein targets (top 14)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | LMNA | P02545 | 2/20 | 0.40 |
| ▸ | KDM4E | B2RXH2 | 1/20 | 0.40 |
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.40 |
| ▸ | GLA | P06280 | 1/20 | 0.40 |
| ▸ | GAA | P10253 | 1/20 | 0.40 |
| ▸ | MPI | P34949 | 1/20 | 0.40 |
| ▸ | GABRA1 | P14867 | 2/20 | 0.37 |
| ▸ | GABRB2 | P47870 | 2/20 | 0.37 |
| ▸ | ELANE | P08246 | 1/20 | 0.36 |
| ▸ | CTSG | P08311 | 1/20 | 0.36 |
| ▸ | TP53 | P04637 | 4/20 | 0.35 |
| ▸ | MAPT | P10636 | 2/20 | 0.35 |
| ▸ | SMN1; SMN2 | Q16637 | 1/20 | 0.35 |
| ▸ | HDAC8 | Q9BY41 | 1/20 | 0.34 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL10027225 | 0.85 | LMNA (0.43) | LMNAKDM4EALDH1A1GLAGAA | |
| SCHEMBL10027188 | 0.82 | LMNA (0.40) | LMNAKDM4EALDH1A1GLAGAA | |
| SCHEMBL13313513 | 0.81 | KDM4E (0.39) | LMNAKDM4EALDH1A1GLAGAA | |
| SCHEMBL17802289 | 0.81 | KDM4E (0.40) | LMNAKDM4EALDH1A1GLAGAA | |
| SCHEMBL17808887 | 0.81 | CHEK1 (0.40) | LMNAKDM4EALDH1A1GLAGAA | |
| SCHEMBL10027187 | 0.80 | LMNA (0.43) | LMNAKDM4EALDH1A1GLAGAA | |
| SCHEMBL10027234 | 0.80 | MAPT (0.43) | LMNAKDM4EALDH1A1GLAGAA | |
| Hydrochloric Acid SCHEMBL17802251 | 0.80 | KDM4E (0.42) | LMNAKDM4EALDH1A1GLAGAA | |
| Hydrochloric Acid SCHEMBL17802250 | 0.78 | CHEK1 (0.39) | LMNAKDM4EALDH1A1GLAGAA | |
| SCHEMBL17808853 | 0.78 | KDM4E (0.39) | LMNAKDM4EALDH1A1GLAGAA |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 1 patent. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20210230159-A1 | 4H-PYRIDO[1,2-A]PYRIMIDIN-4-ONE COMPOUNDS | PRANA BIOTECHNOLOGY LIMITED (AU) | 2021-07-29 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20210230159-A1 | 4H-PYRIDO[1,2-A]PYRIMIDIN-4-ONE COMPOUNDS | PSEN2, PSEN1, PNPO | LMNA 1246/4885KDM4E 2827/4885ALDH1A1 299/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.